| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Filing example | IND | — | Subscribe to access the data. | Gene Therapies | Ophthalmologic System | ||
IND Filing example | IND | — | Subscribe to access the data. | Gene Therapies | Ophthalmologic System | ||
IND Filing example | IND | — | Subscribe to access the data. | Gene Therapies | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Abeona Therapeutics Inc.$6.98
-0.14 (-1.97%)
C 47Pipeline Score Fair Value Pharma · Commercial
Market Cap
324.30 M
EPS
1.30
P/E Ratio
6.07 $
Value Trade
4.73 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
8.72 M
R&D Expenses
9.55 M
Operating CF
-19.80 M
Total Assets
198.49 M
Total Liabilities
53.55 M
Equity
144.94 M
D/E Ratio
12,345
-2.86 %
Week
0.37 %
1 Month
4.02 %
3 Month
29.22 %
6 Month
-86.4 %
5 Year
-100 %
All Time
Cash Data
Cash Position
168.27 M
Monthly Burn
6.60 M
Runway
23.8 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
1.63 M
52 Week Range
4 - 7.54
% held by Insiders
11.8 %
% held by Institutions
69.46 %
Enterprise Value
179.20 M
Total Shares
57.01 M
Short %
28.12 %
Float Shares
47.37 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Abeona Therapeutics Inc.
883Total events
2Upcoming
143Tier-1 (high impact)
2014 – 2026Coverage
Upcoming catalysts 2
Event history 881
Jun 8, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference Investor Meetings
Jun 4, 2026
Jun 2026
●Manufacturing MilestoneZEVASKYNApprovedCMC / Inspection
Scale-up supply capacity to 10 patients per month by mid-2026
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
May 11, 2026
▲Product LaunchZEVASKYNApprovedPost-Market
Activation of Children's Hospital of Philadelphia as sixth Qualified Treatment Center for ZEVASKYN
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
Apr 2, 2026
▲Product LaunchZEVASKYNApprovedPost-Market
Activation of NewYork-Presbyterian/Columbia University Irving Medical Center as fifth Qualified Treatment Center for ZEVASKYN
recessive dystrophic epidermolysis bullosasource ↗
Q2 2026
◆IND Enabling CompleteABO-503Preclinical
Anticipates completing IND-enabling studies in second half of 2026
X-linked retinoschisis (XLRS)source ↗
Q2 2026
▲Product LaunchZEVASKYNApprovedPost-Market
One patient treated with ZEVASKYN in Q2 2026 to date
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
Q2 2026
◆Enrollment UpdateZEVASKYNApprovedTrial
Six additional patients expected to be biopsied in Q2 2026
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
Mar 10, 2026
Drug Pipeline Intelligence
C47
Pipeline Score $281M
Pipeline ValueFair Value
Valuation Signal6
Drugs Scored0.9x
rNPV / MCap Top 71%
Micro Cap (rank 265 of 911)
Percentile RankAbeona Therapeutics Inc. carries a moderate pipeline score (47/100), with $1.8B risk-adjusted pipeline value, led by ofloxacin in Diabetic Foot Ulcers (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ofloxacin Small molecule | Diabetic Foot Ulcers | Phase 3 | NCT00563433 | 68% | $879M | COMPLETED | 926 | - | - | Jul 1, 1996 | - | Sep 3, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ZEVASKYN PriorityOrphanRare Pediatric | recessive dystrophic epidermolysis bullosa | Phase 3 | 2025-06-24 | significant improvements in wound healing and pain reduction following a single treatment Read More | Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa Read More | |
ZEVASKYN PriorityOrphanRare Pediatric | recessive dystrophic epidermolysis bullosa | Phase 3 | 2025-06-24 | significant improvements in wound healing and pain reduction following a single treatment Read More | Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa Read More | |
ZEVASKYN PriorityOrphanRare Pediatric | recessive dystrophic epidermolysis bullosa | Phase 3 | 2025-06-24 | significant improvements in wound healing and pain reduction following a single treatment Read More | Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ABEO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ABEO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
ABEO Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Real-Time ABEO Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
ABEO Option Volume & Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ABEOAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics announced the granting of equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4). On May 31, 2026, the company's Compensation Committee approved 13,800 restricted shares as an inducement for the seven newly hired individuals. The vesting period for these awards spans three years, contingent upon continued employment. This move underscores Abeona's strategy to attract and retain talented personnel as it continues to develop its pipeline of cell and gene therapies.
Read more →ABEOAbeona Therapeutics Announces Participation in Upcoming Investor Conferences
Abeona Therapeutics Inc. will participate in significant investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. The management team will engage with investors, highlighting their focus on advancing cell and gene therapies for serious diseases. The events will also feature a live webcast of a fireside chat, accessible on their website. This engagement reflects Abeona's commitment to their innovative therapies and maintaining investor relations.
Read more →ABEOAbeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
Abeona Therapeutics reported strong first quarter results for 2026, highlighting increased adoption of ZEVASKYN with three patients treated. The company expanded its qualified treatment center network to six sites, enhancing patient access. Financially, Abeona saw a significant rise in net product revenue, although it also reported a net loss of $(17.1) million for the quarter.
Read more →ABEOAbeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
Abeona Therapeutics has announced the activation of the Children's Hospital of Philadelphia as a Qualified Treatment Center for ZEVASKYN, a gene-modified therapy for recessive dystrophic epidermolysis bullosa (RDEB). This collaboration aims to improve access to treatment for patients in the east coast. ZEVASKYN has demonstrated significant wound healing and pain reduction, although there are potential risks associated with its use.
Read more →ABEO▲ +9.6%on this news
Abeona Therapeutics® Announces Date of First Quarter Financial Results
Abeona Therapeutics Inc. announced a conference call scheduled for May 13, 2026, to discuss its first quarter financial results and corporate progress. The call will be accessible via phone and webcast. The company is known for its ZEVASKYN gene therapy, which targets recessive dystrophic epidermolysis bullosa, and is actively developing additional therapies.
Read more →ABEOAbeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
Abeona Therapeutics has appointed Keith A. Goldan to its Board of Directors as of April 1, 2026. Goldan, who has over two decades of financial leadership experience, will also chair the Audit Committee. His expertise is anticipated to support Abeona's growth as a commercial-stage biotech company, particularly in advancing its strategic priorities.
Read more →ABEO▲ +5.2%on this newsshared move
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
Abeona Therapeutics has activated NewYork-Presbyterian/Columbia University Irving Medical Center as a Qualified Treatment Center for ZEVASKYN, enhancing patient access in the Northeast. This partnership aims to provide world-class care for patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is the first gene-modified cellular therapy for this condition, demonstrating significant healing potential.
Read more →ABEOAbeona Therapeutics Reports Full Year 2025 Financial Results and Corporate Updates - First ZEVASKYN commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 - - $191.
Abeona Therapeutics announced its full-year financial results for 2025, revealing significant developments related to its gene therapy ZEVASKYN. The first commercial treatment for ZEVASKYN was successfully completed in December 2025, with a growing demand expected as more patients experience the therapy. The company reported total revenues of $5.8 million, driven by the initial treatment and license revenues, while cash reserves reached $191.4 million. Abeona is also expanding access to ZEVASKYN by activating new treatment centers, positioning itself for increased patient throughput in 2026.
Read more →ABEO▲ +6.4%on this news
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
Abeona Therapeutics has reported significant progress in the commercial launch of ZEVASKYN, an FDA-approved gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has initiated treatment for patients and secured coverage from major payers. However, there are risks associated with the therapy, including potential cancer development and serious allergic reactions.
Read more →ABEOAbeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
Abeona Therapeutics Inc. will host a conference call on March 17, 2026, to discuss its fourth quarter and full year 2025 financial results. The company will also participate in the 2026 Leerink Global Healthcare Conference on March 10, 2026. Abeona's ZEVASKYN is the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa.
Read more →ABEOAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics has announced the granting of equity awards to new non-executive employees as part of its recruitment strategy. The awards, totaling up to 28,676 restricted shares, are designed to incentivize new hires and will vest over three years. Abeona is known for its development of gene therapies, particularly ZEVASKYN, which targets recessive dystrophic epidermolysis bullosa.
Read more →ABEOAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 31, 2025
Abeona Therapeutics has granted equity awards to seven new employees as part of its growth strategy, in compliance with Nasdaq Listing Rule 5635(c)(4). The awards consist of up to 79,584 restricted shares that will vest over three years. Abeona continues to develop its gene therapy, ZEVASKYN, for serious diseases, while facing various commercialization risks.
Read more →ABEO▼ -5.2%on this news
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
Abeona Therapeutics has appointed Mohamad Tabrizi as Chief Business Officer. Tabrizi, who has a strong background in strategic planning and business development, will focus on enhancing the company's corporate strategy and operational efficiency. His previous experience includes significant roles in venture capital and corporate development, suggesting a promising future for Abeona under his leadership.
Read more →ABEOAbeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
Abeona Therapeutics has announced the activation of The University of Texas Medical Branch (UTMB) as a Qualified Treatment Center for ZEVASKYN, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). This partnership aims to enhance patient access to this innovative treatment across Texas and the Gulf Coast. UTMB's expertise in dermatology positions it as a key player in delivering this therapy to patients in need.
Read more →ABEO▲ +5.3%on this newsshared move
Abeona Therapeutics Announces First Patient Treatment with ZEVASKYN Gene Therapy
Abeona Therapeutics announced the first patient treatment using its FDA-approved ZEVASKYN gene therapy, aimed at treating refractory wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The treatment was successfully administered at Lucile Packard Children’s Hospital Stanford, marking a significant step for the company and the RDEB community. CEO Vish Seshadri highlighted the accomplishment as a testament to the team's dedication. Despite the positive advancements, there are noted risks associated with the therapy, including allergic reactions and potential long-term cancer monitoring requirements.
Read more →ABEO▲ +18.5%on this news
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
Abeona Therapeutics reported its third quarter 2025 financial results, highlighting a shift in the anticipated treatment start for ZEVASKYN to the fourth quarter. The company noted strong patient demand and a robust treatment site network, which supports its commercial goals. With $207.5 million in cash reserves, Abeona expects to sustain operations for over two years despite increased expenses related to the product launch.
Read more →ABEOAbeona Therapeutics Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
Abeona Therapeutics Inc. has announced a conference call scheduled for November 12, 2025, to review its third quarter financial results and corporate progress. Additionally, management will participate in a fireside chat at the Stifel 2025 Healthcare Conference on November 13, 2025. Abeona is focused on developing cell and gene therapies, particularly highlighting its autologous cell-based gene therapy, ZEVASKYN, aimed at treating recessive dystrophic epidermolysis bullosa. The company emphasizes its commitment to transparency through accessible live webcasts and archive sessions.
Read more →ABEOAbeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
Abeona Therapeutics has announced that the Centers for Medicare and Medicaid Services has established a permanent J-code for ZEVASKYN, its gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa. The new J-code, effective January 1, 2026, aims to streamline reimbursement processes and enhance patient access. This development is seen as a significant step forward for the therapy's launch.
Read more →ABEOAbeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
Abeona Therapeutics has appointed Dr. James A. Gow as Senior Vice President, Head of Clinical Development & Medical Affairs. Dr. Gow brings over 20 years of experience in clinical development, particularly in gene therapy for inherited retinal diseases. His expertise is expected to significantly advance Abeona's pipeline and treatment offerings.
Read more →ABEOAbeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
Abeona Therapeutics announced that its ABO-503 gene therapy for X-linked retinoschisis (XLRS) has been selected for the FDA's Rare Disease Endpoint Advancement (RDEA) Pilot Program. This program aims to facilitate the development of therapies for rare diseases by allowing the use of novel efficacy endpoints. The selection is expected to enhance collaboration with the FDA and improve clinical development efforts for XLRS, a condition with significant unmet medical needs.
Read more →ABEO▲ +5.5%on this newsshared move
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
Abeona Therapeutics and Children's Hospital Colorado have announced the activation of Children's Colorado as a Qualified Treatment Center for ZEVASKYN, a gene-modified therapy for recessive dystrophic epidermolysis bullosa (RDEB). This FDA-approved treatment aims to improve wound healing in patients. The collaboration is expected to enhance access to this innovative therapy and improve the quality of life for those affected by RDEB.
Read more →ABEOAbeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Abeona Therapeutics Inc. has announced its participation in upcoming investor conferences in September 2025. The company is known for its development of cell and gene therapies, particularly ZEVASKYN, which treats recessive dystrophic epidermolysis bullosa. The events will be accessible via a live webcast, with replays available on their website.
Read more →ABEO▲ +10.2%on this news
Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates - Received FDA approval for ZEVASKYN (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatm
Abeona Therapeutics reported strong second quarter results for 2025, highlighted by the FDA approval of ZEVASKYN, the first autologous cell-based gene therapy for wounds due to recessive dystrophic epidermolysis bullosa (RDEB). The company is on track to launch ZEVASKYN in the third quarter of 2025, having secured significant insurance coverage and strong demand from identified patients. Abeona's financials reflect a healthy cash position, projected to fund operations well into the future, with anticipated revenue beginning in Q3 2025 and projected profitability by H1 2026. The company is also engaged in collaborations to expand treatment options within the gene therapy landscape.
Read more →ABEO▲ +5.4%on this news
Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
Abeona Therapeutics Inc. announced the completion of its sale of a Rare Pediatric Disease Priority Review Voucher for $155 million. This sale significantly enhances the company's financial position, providing over two years of operating capital without needing further funding. The company expects to start treating patients with its approved gene therapy, ZEVASKYN, in Q3 2025, with forecasts of profitability in early 2026. However, risks related to commercialization and market conditions remain highlighted in their forward-looking statements.
Read more →ABEOAbeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Abeona Therapeutics announced that Beacon Therapeutics has exercised its option to license the AAV204 capsid for gene therapies targeting retinal diseases. This license, a continuation of the partnership initiated in July 2024, allows Beacon to utilize AAV204 across multiple ophthalmic disease targets. The arrangement includes upfront license payments and milestone-driven royalties for Abeona. AAV204's performance in preclinical studies indicates its effectiveness in delivering gene therapies, offering a potential solution for patients with conditions that lead to blindness.
Read more →ABEOAbeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index
Abeona Therapeutics Inc. has been added to the U.S. small-cap Russell 2000 Index and the broad-market Russell 3000 Index, effective immediately. This announcement follows the FDA approval of its gene therapy product ZEVASKYN. The company’s CFO highlighted that this inclusion could amplify their momentum and broaden investor engagement. The Russell indexes are essential benchmarks for many investment strategies.
Read more →ABEOAbeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million Cash resources totaled approximately $225 million as of
Abeona Therapeutics Inc. has successfully completed the sale of its Rare Pediatric Disease Priority Review Voucher for $155 million. This sale significantly boosts the company's financial resources, which total approximately $225 million, ensuring over two years of operating capital. Additionally, Abeona anticipates beginning patient treatment with its gene therapy ZEVASKYN in Q3 2025 and expects profitability by early 2026.
Read more →ABEOAbeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics announced the publication of Phase 3 VIITAL study results in The Lancet, showcasing ZEVASKYN's effectiveness in treating wounds associated with recessive dystrophic epidermolysis bullosa (RDEB). The study demonstrated significant improvements in wound healing and pain reduction following a single treatment. ZEVASKYN is notable as the first FDA-approved cell-based gene therapy for RDEB. The company aims to improve patient outcomes as the product's U.S. launch processes are underway.
Read more →ABEOAbeona Therapeutics to Present at the Jefferies Global Healthcare Conference
Abeona Therapeutics Inc. announced that its CEO, Vish Seshadri, and CCO, Madhav Vasanthavada, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025. The event will provide insights into the company's ongoing efforts in developing gene therapies, particularly for rare diseases. A live webcast will be available on their website and archived for 30 days for those unable to attend. This participation underscores Abeona's commitment to advancing its therapeutic portfolio in the biopharmaceutical sector.
Read more →ABEO▲ +7.4%on this news· ran to +19% by day 3
Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates - Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN (prademagene zamikeracel), the first and only autologous
Abeona Therapeutics Inc. has reported its first quarter 2025 financial results alongside significant updates, including FDA approval for ZEVASKYN (prademagene zamikeracel), the first autologous cell-based gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The company is actively launching ZEVASKYN in the U.S., with the first qualified treatment center now operational. Additionally, the company has secured a $155 million sales agreement for a priority review voucher, enhancing its financial outlook as it prepares for commercialization. Abeona anticipates activating more treatment centers by the end of 2025 to facilitate patient access.
Read more →ABEOAbeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
Abeona Therapeutics and Ann & Robert H. Lurie Children's Hospital have launched ZEVASKYN, the first commercially available gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). Lurie Children's has been activated as the initial Qualified Treatment Center for the therapy, which has recently received FDA approval. This groundbreaking treatment aims to provide significant relief and healing to patients suffering from painful skin conditions. The first treatments are anticipated to commence in the third quarter of 2025.
Read more →ABEO▲ +6.3%on this newsshared move
Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million CLEVELAND
Abeona Therapeutics Inc. has announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $155 million. The proceeds will provide the company with enough cash to support operations for over two years. Following FDA approval for ZEVASKYN, the company expects the treatment to be available to patients by the third quarter of 2025, with plans for profitability in early 2026. The transaction is subject to standard closing conditions, including a review under the Hart-Scott Rodino Antitrust Improvements Act.
Read more →ABEOU.S. FDA Approves ZEVASKYN (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) - ZEVASKYN fills a critical need for people living with
The FDA has approved ZEVASKYN (prademagene zamikeracel), the first cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). This innovative treatment demonstrated significant improvements in wound healing and pain reduction after single application, as seen in the Phase 3 VIITAL study. ZEVASKYN will be available through Qualified Treatment Centers starting in Q3 2025, with additional support offered to patients through the Abeona Assist program. Experts in dermatology express optimism regarding its potential to transform care for RDEB patients, addressing a critical unmet medical need.
Read more →ABEOAbeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription
Abeona Therapeutics reported its financial results for 2024 while providing an update on the regulatory status of prademagene zamikeracel (pz-cel). The FDA is conducting a priority review of the BLA for pz-cel, with a target action date set for April 29, 2025. The company plans to treat its first patient by Q3 2025, contingent upon FDA approval. Abeona also announced expansion efforts in manufacturing and commercialization in anticipation of a successful product launch.
Read more →ABEOAbeona Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Abeona Therapeutics Inc. has announced that its CEO, Vish Seshadri, will present at the Leerink Partners Global Healthcare Conference on March 10, 2025. The presentation will discuss the company's ongoing development of innovative cell and gene therapies, including investigational products for serious diseases. Interested parties can access a live webcast of the event via Abeona's investor relations webpage. The announcement reflects Abeona's commitment to transparency and investor engagement while highlighting its novel therapeutic approaches.
Read more →ABEOAbeona Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of
Abeona Therapeutics reported its third quarter 2024 financial results and highlighted recent corporate updates regarding its investigational gene therapy, pz-cel, for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has accepted the resubmission of Abeona's Biologics License Application (BLA) and set a target action date of April 29, 2025. The company is focusing on commercialization efforts, including payer discussions and treatment site onboarding, while also developing its manufacturing capacity in Cleveland. Despite a reported net loss, Abeona continues to progress towards potential commercialization of pz-cel in 2025.
Read more →ABEO▼ -5.1%on this newsshared move
Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa FDA assigns PDUFA target action date of
Abeona Therapeutics announced that the FDA has accepted its Biologics License Application (BLA) resubmission for pz-cel, an investigational gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025. If approved, pz-cel would be the first gene therapy to target COLL7A1 mutations responsible for RDEB, offering hope for improved treatment outcomes. Support for the resubmission includes substantial clinical efficacy and safety data from multiple studies.
Read more →ABEOAbeona Therapeutics Announces Participation in November Investor Conferences
Abeona Therapeutics Inc. announced its participation in two upcoming investor conferences in November 2024, indicating its ongoing engagement with the financial community. The company will hold meetings at the Truist Securities BioPharma Symposium and participate in a fireside chat during the Stifel 2024 Healthcare Conference. Abeona is known for its work in developing cell and gene therapies for serious conditions, including its investigational treatment for recessive dystrophic epidermolysis bullosa. Despite its advancements, Abeona acknowledges potential risks related to FDA review processes and market conditions.
Read more →ABEOAbeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration CLEVELAND
Abeona Therapeutics has resubmitted its Biologics License Application (BLA) for prademagene zamikeracel (pz-cel) to the FDA as a gene therapy aimed at treating recessive dystrophic epidermolysis bullosa (RDEB). This resubmission follows the FDA's feedback addressing Chemistry Manufacturing and Controls requirements. The FDA previously required additional information but did not cite deficiencies in clinical efficacy or safety data, nor request new clinical trials. The acceptance of this resubmission is expected to lead to a new review period determined by the FDA's classification of the submission.
Read more →ABEOAbeona Therapeutics Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors CLEVELAND
Abeona Therapeutics Inc. has appointed Bernhardt G. Zeiher, MD, and Eric Crombez, MD, as new independent members of its Board of Directors. Dr. Zeiher brings over 20 years of experience in drug development, having overseen the approval of numerous treatments. Dr. Crombez has expertise in clinical development programs for rare genetic disorders and currently serves as Chief Medical Officer at Ultragenyx Pharmaceutical. Their appointments are seen as crucial for advancing Abeona's commitment to developing therapies for serious diseases, notably the investigational therapy pz-cel for recessive dystrophic epidermolysis bullosa.
Read more →ABEOAbeona Therapeutics Announces Favorable Medicare Reimbursement Decisions for Pz-cel
Abeona Therapeutics announced that the Centers for Medicare and Medicaid Services (CMS) has granted a product-specific procedure code for its gene therapy pz-cel, intended for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). This decision, effective October 1, 2024, allows for streamlined documentation and billing. Additionally, pz-cel has been assigned to a high Medicare reimbursement category, enhancing the financial support for its use once approved. The company expressed optimism regarding access and reimbursement as they continue to develop this innovative therapy.
Read more →ABEO▲ +12%on this newsshared move
Abeona Therapeutics Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission Significant progress addressing CMC items noted in CRL BLA resubmission
Abeona Therapeutics has reported its second quarter 2024 financial results and announced that it has concluded a Type A meeting with the FDA regarding its planned Biologics License Application resubmission for prademagene zamikeracel (pz-cel). The company is addressing Chemistry Manufacturing and Controls deficiencies noted in the FDA's Complete Response Letter and is on track for resubmission later this year. Financially, Abeona saw a notable net income of $7.4 million in Q2 2024, compared to a loss in the same period last year. The upcoming resubmission aims to provide a new treatment option for patients with recessive dystrophic epidermolysis bullosa.
Read more →ABEOAbeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
Abeona Therapeutics has entered a non-exclusive agreement with Beacon Therapeutics to evaluate the therapeutic potential of Abeona's patented AAV204 capsid for specific ophthalmology applications. This partnership allows Beacon to assess AAV204 for a 12-month period, with rights to develop and commercialize therapies for up to five gene or disease targets. Abeona will receive upfront and milestone payments, with the goal of enhancing treatment options for patients suffering from retinal diseases.
Read more →ABEO▲ +5.7%on this newsshared move
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
Abeona Therapeutics Inc. announced that its CEO, Vish Seshadri, and CCO, Madhav Vasanthavada, will participate in a virtual fireside chat at the Stifel Virtual Cell Therapy Forum on July 9, 2024. The event will be accessible via a live webcast on Abeona's investor page and archived for 30 days. The company is primarily focused on developing cell and gene therapies for serious diseases, including its investigational product for epidermolysis bullosa. However, they noted potential risks related to FDA submissions and regulatory approvals.
Read more →ABEO▲ +12.1%on this news
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash
Abeona Therapeutics reported its financial results for the first quarter of 2024, highlighting a $75 million underwritten offering that extends its cash runway into 2026. The company is preparing to resubmit its Biologics License Application (BLA) for prademagene zamikeracel (pz-cel) in response to the FDA's Complete Response Letter, which flagged Chemistry Manufacturing and Controls (CMC) deficiencies but did not question the clinical efficacy data. The anticipated resubmission is expected in the second half of 2024, while new safety data will be presented at upcoming medical meetings.
Read more →ABEO▲ +13%on this newsshared move
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants CLEVELAND
Abeona Therapeutics Inc. announced the pricing of a $75 million underwritten offering, which consists of 12,285,056 shares of common stock and pre-funded warrants for an additional 6,142,656 shares. The offering price is set at $4.07 per share, aligning with the previous market close. Proceeds from this offering will primarily fund preparations for the resubmission of its Biologics License Application for the product candidate pz-cel, aimed at treating recessive dystrophic epidermolysis bullosa. Closing of the offering is expected on May 7, 2024, subject to customary conditions.
Read more →ABEO▼ -53.7%on this news
Abeona Therapeutics Provides Regulatory Update on Pz-cel Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical
Abeona Therapeutics announced that the FDA issued a Complete Response Letter (CRL) for its biologics license application (BLA) for pz-cel, necessitating additional Chemistry Manufacturing and Controls (CMC) information. Importantly, the FDA did not indicate any deficiencies in clinical efficacy or safety data and did not require new clinical trials. Abeona is committed to addressing the CMC requests and aims for a resubmission by the third quarter of 2024. The timeline proposed by the company may not allow enough time for FDA review by the original PDUFA date of May 25, 2024.
Read more →ABEO▼ -19%on this news
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections - FDA completed Pre-License Inspection of Abeona's Cleveland manufacturing facility, as well as inspection of clini
Abeona Therapeutics reported its full year 2023 financial results and provided an update on its FDA inspections. The FDA completed a Pre-License Inspection of its Cleveland manufacturing facility, observing the pz-cel production process and issuing a Form 483 for process controls. However, clinical trial site inspections at Stanford University and UMass had no noted issues. The FDA has set a Prescription Drug User Fee Act date for May 25, 2024, as Abeona prepares for a potential launch of pz-cel for recessive dystrophic epidermolysis bullosa.
Read more →ABEO▲ +5.7%on this news
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
Abeona Therapeutics Inc. has announced a progress update on its Biologics License Application (BLA) for pz-cel, aimed at treating recessive dystrophic epidermolysis bullosa (RDEB). The FDA's BIMO inspection of the company was completed without any adverse findings, and the BLA mid-cycle review confirmed the PDUFA target action date of May 25, 2024. The FDA also indicated it does not plan to hold an Advisory Committee meeting for the pz-cel application, suggesting a smoother review process ahead.
Read more →ABEOAbeona Therapeutics Announces $50 Million Credit Facility CLEVELAND
Abeona Therapeutics announced a $50 million credit facility with Avenue Venture Opportunities Fund to bolster its commercialization plans for pz-cel, an investigational gene therapy. This facility includes an initial $20 million, followed by additional tranches if certain conditions are met. With a PDUFA target action date set for May 25, 2024, for the FDA's review of pz-cel, the company is positioned to potentially launch the product soon. The funds will also allow for general corporate purposes and extend the company's financial reach.
Read more →ABEO▲ +11.6%on this news
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) - PDUFA target action date is
Abeona Therapeutics announced that the FDA has accepted and granted Priority Review for its Biologics License Application for pz-cel, an investigational treatment for recessive dystrophic epidermolysis bullosa (RDEB). The target action date is set for May 25, 2024, with no Advisory Committee meeting planned. This review highlights the urgent need for effective therapies for RDEB, supported by data from clinical studies demonstrating the potential benefits of pz-cel in wound healing and pain reduction. Abeona's development efforts and manufacturing capabilities will play a crucial role as they move forward in this regulatory process.
Read more →ABEO▲ +10%on this news
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments Abeona's first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority rev
Abeona Therapeutics reported its third quarter 2023 financial results, highlighting the completion of its first U.S. Biologics License Application (BLA) for pz-cel in September 2023. A FDA decision on the BLA is expected by late November 2023. The company is preparing for a potential U.S. launch, having raised $25 million to bolster its commercial readiness. However, the company reported a net loss increase, emphasizing ongoing financial challenges.
Read more →ABEO▲ +9.8%on this news
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics has submitted a Biologics License Application (BLA) to the FDA for EB-101, an autologous cell therapy targeting recessive dystrophic epidermolysis bullosa (RDEB). The company requested a Priority Review to expedite the FDA's review process. This submission is backed by clinical data demonstrating the therapy's efficacy and safety from a pivotal Phase 3 study. If approved, EB-101 would become the first individualized cell therapy aimed specifically at addressing RDEB, potentially enhancing the quality of life for affected patients.
Read more →ABEOAbeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
Abeona Therapeutics Inc. has appointed Madhav Vasanthavada, Ph.D., M.B.A., as its new Chief Commercial Officer and Head of Business Development. In this role, he will oversee the company's commercial strategy in preparation for the potential launch of EB-101, a genetically engineered cell therapy aimed at treating recessive dystrophic epidermolysis bullosa. Dr. Vasanthavada's extensive experience in launching autologous therapies is expected to enhance Abeona's market presence as the company transitions to a commercial-stage organization. His appointment is seen as timely, given the anticipated approval timeline for EB-101 in the U.S.
Read more →ABEO▲ +5.6%on this news
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
Abeona Therapeutics has announced its intent to submit a Biologics License Application (BLA) for EB-101, an engineered cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). Following a productive pre-BLA meeting with the FDA, the company believes its clinical efficacy and safety data are adequate for the submission. The FDA has requested supplementary data to support the potency and identity assays of EB-101. With the positive feedback from the FDA, Abeona aims to submit the BLA early this fall.
Read more →ABEOAbeona Therapeutics Reports Second Quarter 2023 Financial Results On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from $25 million registered direct offering in July allow in
Abeona Therapeutics reported its second quarter 2023 financial results, highlighting its progress toward a Biologics License Application (BLA) submission for EB-101, focused on treating recessive dystrophic epidermolysis bullosa (RDEB). The company successfully completed significant milestones, including preparations for a commercial launch and generating required FDA data for its BLA submission. Financially, Abeona raised $25 million to extend its operational runway and decrease substantial net losses. The company anticipates submitting the BLA in the third quarter of 2023 after presenting favorable results from its Phase 3 clinical study.
Read more →ABEO▲ +5.4%on this news
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
Abeona Therapeutics Inc. has completed the submission of a briefing package for its pre-Biologics License Application (BLA) meeting with the FDA scheduled for August 2023. The meeting aims to discuss data related to the company's investigational therapy, EB-101, for treating recessive dystrophic epidermolysis bullosa. Additionally, the company has generated further data required by the FDA to establish comparability of retroviral vectors used in clinical studies. The anticipated BLA submission for EB-101 is expected in the third quarter of 2023.
Read more →ABEOAbeona Therapeutics Joins Rare Disease Company Coalition
Abeona Therapeutics Inc. has joined the Rare Disease Company Coalition, an alliance aimed at improving therapies for patients with rare diseases. CEO Vish Seshadri has been appointed to the coalition's Board of Directors, indicating Abeona's commitment to advocacy and collaboration within the rare disease community. The RDCC focuses on addressing the unique challenges associated with developing treatments for smaller patient populations, enabling continued innovation and access to therapies. Abeona's lead program, EB-101, targets recessive dystrophic epidermolysis bullosa, highlighting the company's mission in rare disease therapy development.
Read more →ABEOAbeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules CLEVELAND
Abeona Therapeutics Inc. has successfully closed a registered direct offering, raising $25 million for the commercialization of its product candidate, EB-101. This offering, which does not include discounts or warrant coverage, reflects the confidence of existing institutional investors. The funds will be primarily used for preparing EB-101's launch, anticipated upon Biologics License Application approval in early 2024. Additionally, EB-101's Rare Pediatric Disease designation positions the company favorably for obtaining a priority review voucher from the FDA.
Read more →ABEO▲ +6.9%on this newsshared move
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules CLEVELAND
Abeona Therapeutics has announced a $25 million registered direct offering primarily aimed at initiating preparations for the commercialization of EB-101, an investigational therapy for recessive dystrophic epidermolysis bullosa. The offering, priced at $4.03 per share, will consist of sales of common stock and pre-funded warrants to existing institutional investors. Abeona expects to utilize the proceeds for launch preparations, working capital, and general corporate purposes. Additionally, successful BLA submission could lead to a priority review voucher from the FDA, which would expedite future marketing applications.
Read more →ABEOAbeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
Abeona Therapeutics Inc. received positive feedback from the FDA regarding the data needed to establish retroviral vector comparability for its Biologics License Application for EB-101. The alignment on this critical Chemistry, Manufacturing and Controls component marks a significant milestone for the company. Abeona is now set to reschedule its pre-BLA meeting to August 2023 and plans to file its application in the third quarter of 2023. The company is developing EB-101 as a treatment for recessive dystrophic epidermolysis bullosa.
Read more →ABEOAbeona Therapeutics to Present at the Jefferies Healthcare Conference
Abeona Therapeutics Inc. will present at the Jefferies Healthcare Conference on June 9, 2023, featuring CEO Vish Seshadri in a fireside chat. The company will also hold one-on-one investor meetings to discuss its developments. Abeona is known for its cell and gene therapies aimed at serious diseases, with key products including EB-101 for recessive dystrophic epidermolysis bullosa. A live webcast of the event will be available on Abeona's website.
Read more →ABEOAbeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
Abeona Therapeutics Inc. has announced a change in the date for its First Quarter 2023 Portfolio Update conference call, moving it from May 23 to May 24, 2023. The call will be held at 8:30 a.m. ET. Interested parties can access the call via telephone or through a live webcast available on Abeona's website. The company specializes in developing cell and gene therapies for serious diseases, particularly focusing on treatments for epidermolysis bullosa.
Read more →ABEOAbeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Abeona Therapeutics announced new preclinical data from its adeno-associated virus (AAV) ophthalmology program at the ASGCT annual meeting. The data presented indicates promising early evidence of gene therapy effectiveness across three candidate therapies targeting various retinal diseases in mouse models. Key findings include successful ABCA4 gene reconstitution and notable improvements in photoreceptor function following treatment. The company anticipates meetings with the FDA to discuss further development of these therapies.
Read more →ABEO▼ -7.2%on this newsshared move
Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
Abeona Therapeutics announced additional positive results from its Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) at the ISID Meeting in Tokyo. The data showed significant wound healing and pain reduction improvements compared to control treatments. Patient-reported outcomes regarding itch severity and blistering also indicated considerable benefits. The study met its co-primary endpoints, highlighting EB-101's potential to enhance the quality of life for RDEB patients.
Read more →ABEO▼ -7.2%on this newsshared move
Abeona Therapeutics Reports First Quarter 2023 Financial Results Continues to make progress toward Biologics License Application (BLA) submission for EB-101 in late-2Q/early-3Q 2023; submitted request for pre-BLA meeting
Abeona Therapeutics reported its first quarter 2023 financial results, highlighting progress towards its Biologics License Application submission for EB-101, anticipated in late Q2 to early Q3. The company has submitted a request for a pre-BLA meeting with the FDA. Recent presentations at industry meetings showcased positive results from the Phase 3 VIITAL study, reinforcing the value of EB-101 in treating recessive dystrophic epidermolysis bullosa. Financial results showed a reduced net loss compared to the previous year, with adequate cash reserves projected to support operations through Q3 2024.
Read more →ABEOAbeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Abeona Therapeutics has announced the acceptance of three abstracts related to its adeno-associated virus (AAV) ophthalmology program at the upcoming ASGCT annual meeting. The abstracts feature data on investigational gene therapies targeting Stargardt disease, X-linked retinoschisis, and autosomal dominant optic atrophy. The company plans to submit pre-IND meeting requests to the FDA for these candidates in the near term. This development highlights Abeona's commitment to advancing gene therapy solutions for serious eye conditions.
Read more →ABEOAbeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL study results announced in 4Q 2
Abeona Therapeutics has announced its financial results for 2022 and provided a corporate update, highlighting plans to submit a Biologics License Application (BLA) for EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) in mid-2023, following positive Phase 3 results. The company has also been progressing its gene therapy candidates for various serious eye diseases and has made new executive appointments to strengthen its leadership. Additionally, Abeona's financial outlook appears stable, with sufficient funds projected to support operations into 2024.
Read more →ABEO▲ +11.5%on this newsshared move
Abeona Therapeutics Announces New Employee Inducement Grants
Abeona Therapeutics Inc. announced the grant of equity awards to six new employees as an inducement for their acceptance of employment. This decision was made in accordance with Nasdaq regulations and reflects the company's commitment to attracting talent. The awards consist of 131,750 restricted shares of common stock, with a portion vesting after one year of continued employment. Abeona is a clinical-stage biopharmaceutical firm focusing on cell and gene therapies for various serious diseases.
Read more →ABEOAbeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
Abeona Therapeutics announced that new data from its Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted for an oral presentation at the ISID 2023 meeting in Tokyo. The study illustrates the efficacy and safety of EB-101, which utilizes gene transfer to address a significant medical need in RDEB patients. This event follows previously reported positive outcomes from the study, highlighting the potential of EB-101 as a treatment option for this rare condition.
Read more →ABEOAbeona Therapeutics Announces Update on AAV Ophthalmology Program
Abeona Therapeutics has announced significant progress in its AAV-based gene therapy program aimed at treating eye diseases such as Stargardt Disease, X-linked Retinoschisis, and Autosomal Dominant Optic Atrophy. The company has reported encouraging preclinical data from animal studies and plans to submit its first pre-IND application meeting request to the FDA. Abeona expects to present new data at a scientific congress in the second quarter of 2023, outlining the potential of its investigational therapies, which address unmet medical needs in the field of ophthalmology.
Read more →ABEO▼ -5.5%on this news
Abeona Therapeutics Reports Third Quarter 2022 Financial Results Following positive topline data from Phase 3 VIITAL study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 C
Therapeutics Reports Third Quarter 2022 Financial Results positive topline data from Phase 3 VIITAL study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. well-funded with expected cash runway into 3Q 2024 YORK and CLEVELAND, November 14, 2022
Read more →ABEO▼ -13.2%on this news
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greater magnitude of pain reduction benefit was observed in post-hoc analysis of EB-1
Read more →ABEO▼ -13.2%on this news
Abeona Therapeutics Announces $35 Million Private Placement Financing NEW YORK and CLEVELAND
Therapeutics Announces $35 Million Private Placement Financing YORK and CLEVELAND, Nov. 3, 2022 (GLOBE NEWSWIRE) - Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of its common stock, and,
Read more →ABEO▼ -8.1%on this news
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered cell therapy, EB-101, in patients with reces
Read more →ABEOAbeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
NEW YORK and CLEVELAND, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has completed their 6-month follow-up visit in Abeona’s pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered cell therapy
Read more →ABEO▼ -9.2%on this news
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30,
Read more →ABEOAbeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel discussion at the Cantor Fitzgerald Cell and Genetic Medicines Conference on Thurs
Read more →ABEO▲ +12%on this news
Abeona Therapeutics Reports Second Quarter 2022 Financial Results Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL study topline data expected in late-3Q/early-4Q 202
Therapeutics Reports Second Quarter 2022 Financial Results of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 3 VIITAL study topline data expected in late-3Q/early-4Q 2022 upon completion of final patient monitoring visit in mid-September wound charact
Read more →ABEOAbeona Therapeutics Regains Compliance with Nasdaq Listing Requirements NEW YORK and CLEVELAND
Therapeutics Regains Compliance with Nasdaq Listing Requirements YORK and CLEVELAND, July 20, 2022 - Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 informing Abeona that it has regained
Read more →ABEOAbeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule NEW YORK, NY and CLEVELAND, OH
Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule YORK, NY and CLEVELAND, OH, May 19, 2022 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has bee
Read more →ABEOAbeona Therapeutics Reports First Quarter 2022 Financial Results Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023 Focus R&D resources on EB-101 pivotal phase 3 VIITAL
Therapeutics Reports First Quarter 2022 Financial Results of MPS programs to reduce operating expenses and projected cash runway into 2Q 2023 R&D resources on EB-101 pivotal phase 3 VIITAL topline data expected in 3Q 2022 YORK and CLEVELAND, May 13, 2022 - Abeona Therapeutics
Read more →ABEO▼ -9.3%on this news· ran to -20% by day 3
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MP
Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA data featured in encore oral presentation at American Society of Gene
Read more →ABEOAbeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates
NEW YORK and CLEVELAND, Ohio, May 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced the presentation of new preclinical data on AAV204 at the Association for Research and Vision in Ophthalmolo
Read more →ABEO▼ -7.1%on this newsshared move
Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock NEW YORK, NY and CLEVELAND, OH
Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock YORK, NY and CLEVELAND, OH, April 29, 2022 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that it has entere
Read more →ABEO▼ -7.1%on this newsshared move
Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
NEW YORK and CLEVELAND, April 29, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that preclinical data on AAV204, a novel adeno-associated virus (AAV) capsid from Abeona’s in-licensed AIM™ caps
Read more →ABEOAbeona Therapeutics Announces Strategy Update and 2021 Financial Results EB-101 pivotal phase 3 VIITAL study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained FDA alignment on CM
Therapeutics Announces Strategy Update and 2021 Financial Results pivotal phase 3 VIITAL study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained FDA alignment on CMC requirements for EB-101 including characterization and validation plan
Read more →ABEOAbeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
NEW YORK and CLEVELAND, March 28, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics, will participate in a panel discussio
Read more →ABEOAbeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEB
NEW YORK and CLEVELAND, March 14, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL™ study. The objective of VIITAL™ is to ev
Read more →ABEOAbeona Therapeutics Issues Letter to Shareholders
NEW YORK and CLEVELAND, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to shareholders. Dear fellow shareholders, We have never been closer to fulfilling our missio
Read more →ABEO▼ -40%on this newsshared move
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants NEW YORK and CLEVELAND
Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants YORK and CLEVELAND, Dec. 17, 2021 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its underwritten public offering of 44,
Read more →ABEO▼ -6.4%on this news· ran to -44% by day 1shared move
Abeona Therapeutics Announces Public Offering of Common Stock and Warrants NEW YORK and CLEVELAND
Therapeutics Announces Public Offering of Common Stock and Warrants YORK and CLEVELAND, Dec. 16, 2021 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and sell shares of its common stock and
Read more →ABEO▼ -9.8%on this news
Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa
NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second annual Venture Into Cures, a virtual event supporting EB Research Partnership's mis
Read more →ABEOAbeona Therapeutics Reports Third Quarter Financial Results Phase 3 VIITAL study on track to complete enrollment in first quarter 2022 with final patients identified and under screening Added gene therapy and biopharmace
Therapeutics Reports Third Quarter Financial Results 3 VIITAL study on track to complete enrollment in first quarter 2022 with final patients identified and under screening gene therapy and biopharmaceutical industry veterans to regulatory and quality teams to prepare for two B
Read more →ABEOAbeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference
NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the company’s ABO-102 pivotal Transpher A study in Sanfilippo syndrome type A (MPS IIIA) w
Read more →ABEOAbeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Executive Officer of Abeona, will participate virtually in a fireside chat at th
Read more →ABEOAbeona Therapeutics Reports Third Quarter Financial Results
Phase 3 VIITAL™ study on track to complete enrollment in first quarter 2022 with final patients identified and under screening Added gene therapy and biopharmaceutical industry veterans to regulatory and quality teams to prepare for two Biologics License Application (BLA) submis
Read more →ABEOAbeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A., Chief Executive Officer of Abeona, is scheduled to present at the Jefferies Ge
Read more →ABEOAbeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021. The pr
Read more →ABEOAbeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice President, Head of Quality. Mr. Voss, who has been advising the Company as a
Read more →ABEOAbeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings Steven H. Rouhandeh to retire as Chairman of the Board; Micha
Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board Seshadri, Ph.D., M.B.A. to become Chief Executive Offi
Read more →ABEOAbeona Therapeutics to Present at Upcoming Investor Conferences
NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company’s management will present and conduct one-on-one meetings at the following virtual i
Read more →ABEOAbeona Therapeutics Appoints Edward Carr as Chief Financial Officer
NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as Chief Financial Officer and Principal Financial Officer, effective immediately.
Read more →ABEOAbeona Therapeutics Reports Second Quarter Financial Results Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL study Successful Type B meeting with U.S. FDA; Transpher A study will serve as the pivota
Therapeutics Reports Second Quarter Financial Results clinical trial site activated in EB-101 pivotal Phase 3 VIITAL study Type B meeting with U.S. FDA; Transpher A study will serve as the pivotal study for ABO-102 in MPS IIIA; Alignment with FDA on primary resources on comple
Read more →ABEOAbeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease Alignment with FDA on primary study endpoint NEW YORK and CLEVELAND, July 28, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therap
Read more →ABEOAbeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
NEW YORK and CLEVELAND, July 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene therapy, today announced magnetic resonance imaging (MRI) data from the Phase 1/2 Transpher A clinical study indicating that ABO-102 increased grey
Read more →ABEOAbeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa
NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITAL™ study of its investigational EB-101
Read more →ABEOAbeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting
NEW YORK and CLEVELAND, July 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical trial results up to six years following treatment with Abeona’s investigational EB-10
Read more →ABEOAbeona Therapeutics to Present at Jefferies Virtual Healthcare Conference
NEW YORK and CLEVELAND, June 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Con
Read more →ABEOAbeona Therapeutics Issues Letter to Stockholders
NEW YORK and CLEVELAND, May 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to stockholders in conjunction with the 2021 Abeona Therapeutics Annual Meeting of Stockholders
Read more →ABEOEvent Type: Q1 2021 Earnings Call Date: 2021-05-25 Company: Abeona Therapeutics, Inc. Ticker: ABEO COMPANY PARTICIPANTS Gregory W. Gin - Vice President-Investor Relations & Corporate Communications Michael Amoroso - Pres
Type: Q1 2021 Earnings Call Abeona Therapeutics, Inc. W. Gin - Vice President-Investor Relations & Corporate Communications Amoroso - President & Chief Executive Officer G. Carr - Chief Accounting Officer & Principal Financial Officer day, ladies and gentlemen and welcome to
Read more →ABEOAbeona Therapeutics Appoints Head of Research & Clinical Development
NEW YORK and CLEVELAND, May 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Vishwas Seshadri, Ph.D., M.B.A., as Senior Vice President, Head of Research & Clinical Developm
Read more →ABEOAbeona Therapeutics Reports First Quarter Financial Results Patient enrollment ongoing for EB-101 pivotal Phase 3 VIITAL study Positive interim MPS III data presented at 17 th Annual WORLDSymposium; additional neurocogni
Therapeutics Reports First Quarter Financial Results enrollment ongoing for EB-101 pivotal Phase 3 VIITAL study interim MPS III data presented at 17th Annual WORLDSymposium; additional neurocognitive assessments of patients treated in high dose cohort 3 in MPS IIIA Transpher A
Read more →ABEOAbeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting
NEW YORK and CLEVELAND, April 20, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data from its preclinical research will be highlighted during an oral presentation at the Association f
Read more →ABEOAbeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors New board members add a wealth of experience in clinical development and manufacturing of cell therapy and gene thera
Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors board members add a wealth of experience in clinical development and manufacturing of cell therapy and gene therapy products YORK and CLEVELAND, Apr. 19, 2021 - Abeona Therapeutics I
Read more →ABEOAbeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors board to bring fresh perspectives, relevant expertise and diverse experience YORK and CLEVELAND, March 25, 2021 (GLOBE NEWSWIRE) - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integr
Read more →ABEOAbeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress Fourth patient treated in pivotal Phase 3 VIITAL study of EB-101 in RDEB after successful Type B meeting with FDA Positive new interim
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress treated in pivotal Phase 3 VIITAL study of EB-101 in RDEB after successful Type B meeting with FDA interim data from MPS IIIA and MPS IIIB programs presented at 17th Annual WORLDSymposium in
Read more →ABEOAbeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
NEW YORK and CLEVELAND, March 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Executive Vice President, Chief Operating Officer (COO) and principal executive officer at
Read more →ABEOAbeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
NEW YORK and CLEVELAND, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February
Read more →ABEONew Positive Phase 1/2 Interim Data Presented at WORLD Symposium Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona's ABO-102 Gene Therapy In addition
Positive Phase 1/2 Interim Data Presented at WORLDSymposium Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona's ABO-102 Gene Therapy addition to preservation of neurocognitive development with ABO-102 in MPS
Read more →ABEOAbeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
NEW YORK and CLEVELAND, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live webinar for the investment community on Tuesday, February 16, 2021 at 1:00 p.m. EST to r
Read more →ABEOAbeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Clinical trial amendment successfully completed for co-prim
Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) trial amendment successfully completed for co-primary endpoints partial wound closure and mean pain reduction YORK and CLE
Read more →ABEOAbeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new interim results from its ABO-102 Phase 1/2 Transpher A study for MPS IIIA and ABO-10
Read more →ABEOAbeona Therapeutics Reports Third Quarter Financial Results Conference call scheduled for Tuesday
Therapeutics Reports Third Quarter Financial Results call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET YORK and CLEVELAND, November 9, 2020 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial resu
Read more →ABEOAbeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior Vice President and Chief Commercial Officer at Abeona, has been promoted to Chief Op
Read more →ABEOE xhibit 99.1 Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer NEW YORK and CLEVELAND
Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer YORK and CLEVELAND, Oct. 27, 2020 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior Vice President and
Read more →ABEOAbeona Therapeutics' Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan Steven H. Rouhandeh Appointed as Chairman of the Board of Directors Jefferies LLC Ret
Therapeutics' Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership H. Rouhandeh Appointed as Chairman of the Board of Directors LLC Retained as Financial Advisor to Assist with the Review of Strategic Options YORK and CLE
Read more →ABEOAbeona Therapeutics Announces Leadership and Board Transitions NEW YORK and CLEVELAND
Therapeutics Announces Leadership and Board Transitions YORK and CLEVELAND, Sep. 28, 2020 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive leadership and Board of Directors. Jo o Siffert, M.D
Read more →ABEOAbeona Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK and CLEVELAND, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will participate in the following upcoming investor conferences. João Siffert, M.D., Chief Exe
Read more →ABEOAbeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease
NEW YORK and CLEVELAND and DALLAS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, t
Read more →ABEOAbeona Therapeutics Reports Second Quarter Financial Results and Business Updates Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs General alignment with CHMP on plans for EU registration of ABO
Therapeutics Reports Second Quarter Financial Results and Business Updates patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs alignment with CHMP on plans for EU registration of ABO-102 for MPS IIIA from RDEB and MPS III programs presented at recent medical meetin
Read more →ABEOAbeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEB Literature review of 65 studies confirms and expands understanding of substantial disease burden of RDEB with considerable clinical, economic and humanistic impact
Read more →ABEOAbeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
NEW YORK and CLEVELAND, July 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Michael Amoroso as Senior Vice President and Chief Commercial Officer (CCO), effective immedia
Read more →ABEOAbeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical programs, highlighted by the restart of patient enrollment in the Company’s pivota
Read more →ABEOAbeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
NEW YORK and CLEVELAND, June 18, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to its clinical program for recessive dystrophic epidermolysis bullosa (RDEB) will be
Read more →ABEOAbeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors NEW YORK and CLEVELAND
Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors YORK and CLEVELAND, Jun. 17, 2020 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced Board of Director appointments that strength
Read more →ABEOAbeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
NEW YORK and CLEVELAND, May 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D., Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on T
Read more →ABEOAbeona Therapeutics Reports First Quarter Financial Results and Business Updates First patient treated in ongoing pivotal Phase 3 VIITAL TM study evaluating EB-101 for RDEB Additional patients dosed in the Phase 1/2 gene
Therapeutics Reports First Quarter Financial Results and Business Updates patient treated in ongoing pivotal Phase 3 VIITALTM study evaluating EB-101 for RDEB patients dosed in the Phase 1/2 gene therapy studies for MPS IIIA and MPS IIIB interim data from MPS III gene therapy
Read more →ABEOAbeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors Company appoints experienced industry leaders Brian Pereira as Executive Chairman and Shawn Tomasello as Independent Board Member N
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors Company appoints experienced industry leaders Brian Pereira as Executive Chairman and Shawn Tomasello as Independent Board Member NEW YORK and CLEVELAND, Apr. 21, 2020 - Abeona Therapeu
Read more →ABEOAbeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and CLEVELAND, April 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced it granted options to Brian Pereira, M.D., the newly-appointed Executive Chairman of the Company, to purchase 93
Read more →ABEOAbeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic
NEW YORK and CLEVELAND, March 27, 2020 (GLOBE NEWSWIRE) -- The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Many institutions and their brave staff of providers are now focused on caring for patients stricken by the virus. We at Abeona
Read more →ABEOAbeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Majority of potential study participants have been pre-screened EB-101 successfully manufactured at Abeona and transplanted at Stanford University Medical Center NEW YORK and CLEVELAND, March 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrat
Read more →ABEOAbeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates On track to treat first RDEB patient in pivotal Phase 3 VIITAL TM study of EB-101 in Q1 2020 Positive interim data from
Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates track to treat first RDEB patient in pivotal Phase 3 VIITALTM study of EB-101 in Q1 2020 interim data from MPS IIIA and MPS IIIB programs presented at WORLDSymposiumTM; of cohort 2 an
Read more →ABEOAbeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
NEW YORK and CLEVELAND, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D., Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Co
Read more →ABEOAbeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™
Neurocognitive development of young MPS IIIA patients preserved up to two years post ABO-102 treatment Dose-dependent and sustained reductions in disease-specific biomarkers denotes clear biologic effects of ABO-102 and ABO-101 First patient treated in cohort 3 of ABO-101 MPS I
Read more →ABEOAbeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa
NEW YORK and CLEVELAND, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the first World Congress on Epidermolysis Bullosa (EB2020), which is convening the world’s l
Read more →ABEOAbeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids
NEW YORK and CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and Trademark Office (USPTO) issued a patent covering next-generation adeno-associa
Read more →ABEOAbeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Study open for enrollment and patient screening underway at Stanford University Company expects first patient to be treated in the first quarter of 2020 EB-101 manufactured at Abeona facility in Cleveland NEW YORK and CLEVELAND, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Abeona Therape
Read more →ABEOABEONA EQUITY LOSS ALERT: ROSEN, A LEADING LAW FIRM, Reminds Abeona Therapeutics Inc. Investors of Important Thursday Deadline in Securities Class Action - ABEO
NEW YORK, Dec. 31, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abeona Therapeutics Inc. (NASDAQ: ABEO) between May 31, 2018 and September 23, 2019, inclusive (the “Class Period”) of the important January 2, 2
Read more →ABEOAbeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its underwritten public offering, with a gross offering size of approximately $103.5 million, whic
Read more →ABEOAbeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA PRIME is sixth regulatory designation for the ABO-102 clinical program NEW YORK and CLEVELAND
Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA PRIME is sixth regulatory designation for the ABO-102 clinical program NEW YORK and CLEVELAND, Dec. 20, 2019 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-inte
Read more →ABEOAbeona Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants NEW YORK and CLEVELAND
Abeona Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants NEW YORK and CLEVELAND, Dec. 20, 2019 (GLOBE NEWSWIRE) - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its public
Read more →ABEOAbeona Therapeutics Announces Public Offering of Common Stock and Pre-Funded Warrants NEW YORK and CLEVELAND
Abeona Therapeutics Announces Public Offering of Common Stock and Pre-Funded Warrants NEW YORK and CLEVELAND, December 19, 2019 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and sell sha
Read more →ABEOAbeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa FDA removes clinical hold; Company may proceed with VIITAL TM study Com
Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis removes clinical hold; Company may proceed with VIITALTM study expects to initiate study in the first quarter of 2020 endpoint confirmed as pro
Read more →ABEOAbeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates Submitted additional EB-101 transport stability data to FDA in response to Clinical Hold Letter; CMC clearance for pivotal VIITAL TM P
Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates Submitted additional EB-101 transport stability data to FDA in response to Clinical Hold Letter; CMC clearance for pivotal VIITAL TM Phase 3 trial anticipated in Q4 2019 Publication of positive lo
Read more →ABEOAbeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress
NEW YORK and CLEVELAND, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the presentations of data from the Transpher A Study, the Company’s ongoing Phase 1/2 clinical trial evaluating A
Read more →ABEOAbeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Sustained wound healing and favorable safety profile observed at three years post-treatment Durable wound healing in large, disabling, chronic wounds EB-101 associated with long-term molecular expression of Type VII collagen protein NEW YORK and CLEVELAND, Oct. 15, 2019 (GLOBE
Read more →ABEOAbeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa Company to provide additional transport stability data points in response to
Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa CLEVELAND, September 23, 2019 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has r
Read more →ABEOCONFIDENTIAL Abeona Therapeutics Announces Strategic Review Company engages Jefferies LLC in response to strategic inbound interest NEW YORK and CLEVELAND
Abeona Therapeutics Announces Strategic Review Company engages Jefferies LLC in response to strategic inbound NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced
Read more →ABEOAbeona Therapeutics Announces Strategic Review
NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies LLC as its financial advisor to assist with the review of strategic options focus
Read more →ABEOMONSIE Living with RDEB Corporate Presentation August 2019 Safe Harbor Statement This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 193
MONSIE Living with RDEB Corporate Presentation August 2019 Safe Harbor Statement This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating to the produc
Read more →ABEOAbeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates Five patients with MPS IIIB treated in the Transpher B Study of ABO-102 gene therapy Positive interim MPS IIIA data showed preservati
Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates patients with MPS IIIB treated in the Transpher B Study of ABO-102 gene therapy interim MPS IIIA data showed preservation of neurocognitive development in youngest patients with robust and s
Read more →ABEOAbeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA Neurocognitive development of youngest patients preserved 12-18 months post treatment; development sc
Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA Neurocognitive development of youngest patients preserved 12-18 months post treatment; development scores remain within range of unaffected children Robust
Read more →ABEOAbeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs
NEW YORK and CLEVELAND, June 26, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Victor Paulus, Ph.D. as Senior Vice President, Regulatory Affairs. The Company also announced
Read more →ABEOAbeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease
NEW YORK and CLEVELAND, June 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its ABO-202 program. ABO-2
Read more →ABEOAbeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
NEW YORK and CLEVELAND, May 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company is cleared to begin a Phase 1/2 clinical trial evaluating its novel, one-time gene therapy ABO-20
Read more →ABEOAbeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)
NEW YORK and CLEVELAND, May 14, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company has completed dosing cohort 1 and treated the first patient in cohort 2 in an ongoing Phase 1/2 c
Read more →ABEOForward Looking Statement This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Ac
Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights CMC work completed in advance of EB-101 Phase 3 VITAL trial expected to begin mid-2019 IND submitted for ABO-202 in CLN1 disease Investor conference call on Tuesday, May NEW YORK and CL
Read more →ABEOAbeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
CMC work completed in advance of EB-101 Phase 3 VITAL™ trial expected to begin mid-2019 IND submitted for ABO-202 in CLN1 disease Investor conference call on Tuesday, May 14 at 10:00 a.m. ET NEW YORK and CLEVELAND, May 10, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nas
Read more →ABEOAbeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data from a completed Phase 1/2 study evaluating EB-101 for the treatment of recessive dy
Read more →ABEOAbeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting
NEW YORK and CLEVELAND, May 01, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that intravitreal administration of the Company’s novel AIM™ AAV204 capsid to non-human primates led to robust tra
Read more →ABEOAbeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting
NEW YORK and CLEVELAND, April 30, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today will report new preclinical data demonstrating that ABO-401, the Company’s novel gene therapy for cystic fibrosis (CF), ef
Read more →ABEOAbeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting
NEW YORK and CLEVELAND, April 15, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data demonstrating the capabilities of the AIM™ capsid library in cystic fibrosis and retinal disorders
Read more →ABEOAbeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
NEW YORK and CLEVELAND, April 04, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABO-101, the
Read more →ABEOActual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to: continued interest in
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results On track to initiate Phase 3 VITAL trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Inv
Read more →ABEOAbeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND
Read more →ABEOAbeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference
NEW YORK and CLEVELAND, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced that João Siffert, M.D., Chief Executive Officer, w
Read more →ABEOAbeona Therapeutics Appoints Jo o Siffert, M.D. Chief Executive Officer Former AveXis Director brings 30 years of experience to the Company NEW YORK and CLEVELAND
Abeona Therapeutics Appoints Jo o Chief Executive Officer Former AveXis Director brings 30 years of experience to the Company NEW YORK and CLEVELAND, Feb. 11, 2019 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel
Read more →ABEOAbeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™
NEW YORK and CLEVELAND, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced that data from ongoing clinical trials for lysosoma
Read more →ABEOAbeona Therapeutics Strengthens Financial Leadership with New Executive Appointments Internal appointments of Christine Silverstein as Chief Financial Officer and Edward Carr as Chief Accounting Officer bolster financial
Abeona Therapeutics Strengthens Financial with New Executive Appointments Internal appointments of Christine Silverstein as Chief Financial Officer and Edward Carr as Chief Accounting Officer bolster financial strategy and controls NEW YORK and CLEVELAND, Jan. 8, 2019 - Abe
Read more →ABEOAbeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day
EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment Expanding Phase I/II study of ABO-102 for Sanfilippo syndrome type A (MPS IIIA) Novel AIMTM AAV vector with CFTR minigene addresses all mutations of Cystic Fibrosis NEW YORK and
Read more →ABEOAbeona Therapeutics 2018 R&D Day MONSIE Living with RDEB 2018 R&D Day
Abeona Therapeutics 2018 R&D Day MONSIE Living with RDEB 2018 R&D Day December 6, 2018 Abeona Therapeutics 2018 R&D Day 8:00 Breakfast / Registration 8:45 "The Edge of Hope" and Opening Remarks 9:00 EB - 101 Review: Pivotal Phase 3 Preparation Jean Tang, M.D., Ph.D., Jay Bircher
Read more →ABEOAbeona Therapeutics to Host R&D Day on December 6, 2018
NEW YORK and CLEVELAND, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced it will host its 2
Read more →ABEOAbeona Therapeutics Announces CEO Transition
NEW YORK and CLEVELAND, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the immediate term
Read more →ABEOAbeona Therapeutics Announces CEO Transition Dr. Carsten Thiel to Depart Company Immediately; Dr. Jo o Siffert Appointed Interim CEO NEW YORK and CLEVELAND
Therapeutics Announces CEO Transition Dr. Carsten Thiel to Depart Company Immediately; Dr. Jo o Siffert Appointed Interim CEO NEW YORK and CLEVELAND, Nov. 26, 2018 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on develo
Read more →ABEOAbeona Announces Participation at the Jefferies 2018 London Healthcare Conference
NEW YORK and CLEVELAND, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that management wi
Read more →ABEOAbeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-th
Read more →ABEOREGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector ROCKVILLE, Md. and
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector ROCKVILLE, Md. and NEW YORK, Nov. 5, 2018 (PRNEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnolo
Read more →ABEOAbeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20 million upfront, $10 million paid upon signing, $10 million by first anniversary of agreement; annual
Read more →ABEOAbeona Announces Participation at Upcoming Conferences
NEW YORK and CLEVELAND, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that management w
Read more →ABEOAbeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
Clinical trial for ABO-101 (AAV-NAGLU) marks the 2nd MPS III program in Europe Company plans to initiate additional clinical sites in European countries including France, Germany and the United Kingdom NEW YORK and CLEVELAND, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeuti
Read more →ABEOAbeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights Investor Conference Call on Friday, August 10 th at 10:00 am ET NEW YORK and CLEVELAND
Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights Investor Conference Call on Friday, August 10th YORK and CLEVELAND - August 09, 2018: Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused
Read more →ABEOAbeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer NEW YORK and CLEVELAND
Abeona Therapeutics Announces Appointments with Max Colao as Chief Commercial Officer NEW YORK and CLEVELAND - July 26, 2018: Abeona Therapeutics Inc. (NASDAQ: ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene therapies for l
Read more →ABEOAbeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference
NEW YORK and CLEVELAND, June 06, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced CEO, Carsten Thiel,
Read more →ABEOAbeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio
-- The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases -- Ribbon-cutting ceremony of gene and cell therapy GMP production center in Ohio to take place May 31 CLEVELAND and NEW YORK,
Read more →ABEOAbeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
ABO-102 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver volumes 11 subjects enrolled through > 4,200 days cumulative follow up NEW YORK and C
Read more →ABEOAbeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
NEW YORK and CLEVELAND, May 17, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening, rare, genetic diseases, announced today updated clinical d
Read more →ABEOAbeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
NEW YORK and CLEVELAND, May 14, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that it is expanding
Read more →ABEOAbeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights Investor Conference Call on Monday, May 14 th at 10:00 am ET NEW YORK and CLEVELAND
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights Investor Conference Call on Monday, May 14th NEW YORK and CLEVELAND - May 11, 2018: Abeona Therapeutics Inc. (NASDAQ: ABEO), a leading clinical- stage biopharmaceutical company focused on
Read more →ABEOAbeona Therapeutics Announces Upcoming Presentations
NEW YORK and CLEVELAND, May 08, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced upcoming presentati
Read more →ABEOAbeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell
Read more →ABEOAbeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European
Read more →ABEOAbeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer NEW YORK and CLEVELAND, April 02, 2018 (GLOBE NEWSWIRE) - Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapi
Read more →ABEOAbeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced financial results
Read more →ABEOAbeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
NEW YORK and CLEVELAND, March 15, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the FDA has g
Read more →ABEOAbeona Therapeutics Announces Upcoming Conference Participation
NEW YORK and CLEVELAND, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the Company’s senio
Read more →ABEOAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
NEW YORK and CLEVELAND, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the FDA has gr
Read more →ABEOA Global Phase 1/2 Clinical Trial of Systemic Gene Transfer of scAAV9.U1a.hSGSH for MPS IIIA: Safety, Tolerability, and Efficacy Kevin M. Flanigan, MD Center for Gene Therapy Nationwide Children's Hospital Columbus, OH 1
A Global Phase 1/2 Clinical Trial of Systemic Gene Transfer of scAAV9.U1a.hSGSH for MPS IIIA: Safety, Tolerability, and Efficacy Kevin M. Flanigan, MD Center for Gene Therapy Nationwide Children's Hospital Columbus, OH 1 Disclosure Information ASGCT 2017 Kevin Flanigan, MD I hav
Read more →ABEOAbeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
ABO-102 results presented at WORLDSymposium for Lysosomal Diseases show significant time- and dose-dependent reduction of underlying disease pathology, including decreased CSF and urine GAGs (HS fragments) and diminished liver volumes Evidence of cognitive benefit at six months
Read more →ABEOAbeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB. ABO-101 is well tolerated and demonstrates early biopotency signals with significant disease-specific heparan sulfate (HS) r
Read more →ABEOAbeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium
NEW YORK and CLEVELAND, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced upcoming oral and p
Read more →ABEOAbeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
First gene therapy RMAT designation for Epidermolysis Bullosa Enables accelerated approval path and real world data usage NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused
Read more →ABEOAbeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
NEW YORK and CLEVELAND, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today that the first patient in a
Read more →ABEOAbeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
Investor Conference Call to be held Monday, November 20th at 10:00 am ET Global enrollment continues in ABO-102 trial for MPS IIIA Screening initiated in ABO-101 Phase 1/2 trial for MPS IIIB Pivotal Phase 3 planning underway for EB-101 program in RDEB NEW YORK and CLEVELAND,
Read more →ABEOAbeona Management to Present at Multiple Conferences in November
NEW YORK and CLEVELAND, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the Company’s senio
Read more →ABEOAbeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
Company Opens European Subsidiary in Spain to Support Global Clinical Development Nine subjects at global clinical sites enrolled to date with more than 2,000 days cumulative follow up assessed NEW YORK and CLEVELAND, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (
Read more →ABEOAbeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares NEW YORK , NY and CLEVELAND, OH - O ctober 19, 2017 -- Abeona Therapeutics Inc.
Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares NY and CLEVELAND, OH - October 19, 2017 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company f
Read more →ABEOAbeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies Nine global foundations collaborate to grant $13.85 million for the continued advancement of
$13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies NEW YORK and CLEVELAND, Oct. 16, 2017 (GLOBE NEWSWIRE) - Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on develo
Read more →ABEOAbeona Therapeutics Announces Public Offering of Common Stock NEW YORK and CLEVELAND
Abeona Therapeutics Announces Public Offering of Common Stock and CLEVELAND, Oct. 16, 2017 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, tod
Read more →ABEOAbeona Therapeutics Announces Pricing of Public Offering of Common Stock NEW YORK and CLEVELAND
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock NEW YORK and CLEVELAND, October 16, 2017 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threate
Read more →ABEOAbeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
ABO-102 Patients Enrolled in Cohort 3 at 3E13 vg/kg Accelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underway Day 30 results demonstrate 67% Heparan sulfate reduction in the CNS and 92% reduction in urinary
Read more →ABEOAbeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
--Demonstrated durable and significant reduction of underlying disease pathology across multiple clinical measures in Cohort 1 (n=3) compared to controls (n=8-12) --Systemic Biopotency demonstrated time- and dose-dependent reductions of disease causing Heparan Sulfate in the Cer
Read more →ABEOAbeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio
-- Facility to support development of advanced gene and cell therapies for treatment of life-threatening rare diseases -- Leaders from local government, life sciences and medical technology to join on October 4 for dedication of first anticipated gene and cell therapy producti
Read more →ABEOAbeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
--Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation --Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics Development and Quality Management CLEVELAND, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Abeona T
Read more →ABEOAbeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa
FDA recently guided Company to accelerate Phase 3 trial for EB-101 autologous cell therapy Breakthrough Therapy designation enables priority review and expedites approval process EB-101 has demonstrated significant efficacy in treated patients for over 2 years Accelerates Phas
Read more →ABEOAbeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017
NEW YORK and CLEVELAND, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced it will host its inaugural Research
Read more →ABEOAbeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A
NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene th
Read more →ABEOAbeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights
NEW YORK and CLEVELAND, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced financial results for the second quarter a
Read more →ABEOAbeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer
NEW YORK and CLEVELAND, July 25, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that Juan Ruiz, M.D., Ph.D., MBA has
Read more →ABEOAbeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
Pivotal Phase 3 clinical trial is planned to commence in early 2018 EB-101 gene therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) has demonstrated promising efficacy and safety in the Phase 1/2 clinical trial EB-101 has received Orphan Drug and Rare Pe
Read more →ABEOAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program
NEW YORK and CLEVELAND, June 29, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA has granted Orphan Drug
Read more →ABEOAbeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
NEW YORK and CLEVELAND, June 02, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced President and CEO, Timothy J. Miller
Read more →ABEOAbeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
NEW YORK and CLEVELAND, May 30, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA has granted Rare Pediatr
Read more →ABEOAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
Abeona’s Third Gene Therapy Program to Receive FDA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in Ongoing Phase 1/2 Clinical Trial NEW YORK and CLEVELAND, May 25, 2017 (GLOBE NEWSWIR
Read more →ABEOAbeona Therapeutics to Present at Multiple Upcoming Conferences
NEW YORK and CLEVELAND, May 19, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced that members of the management team will pr
Read more →ABEOAbeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights
NEW YORK and CLEVELAND, May 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced financial results for the first quarter and
Read more →ABEOAbeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT
--Positive dose response in central nervous system with 60.7% +/- 8.8% reduction of disease-causing heparan sulfate GAG observed in Cohort 2 --Reduction of disease manifestation observed in decreased liver volume of 14.81% (+/- 1.2%) --ABO-102 well-tolerated in six subjects thr
Read more →ABEOAbeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA
NEW YORK and CLEVELAND, May 09, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced Australian regulatory approval to ini
Read more →ABEOAbeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting
NEW YORK and CLEVELAND, May 08, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that data from the Company's gene the
Read more →ABEOAbeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference
--EB-101 Demonstrates Significant Wound Healing (defined as greater than 50% healed) in 100% of Treated Wounds (36/36) at 3 Months; 89% (32/36) at 6 months, 83% (20/24) at 12 months, 88% (21/24) at 24 Months and 100% (6/6) at 36 months Post-Administration --Clinical Endpoints Su
Read more →ABEOAbeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting
NEW YORK and CLEVELAND, April 25, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced that updated Phase 1/2 clin
Read more →ABEOAbeona to Present At Multiple Upcoming Conferences
NEW YORK and CLEVELAND, April 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced President and CEO, Timothy
Read more →ABEOAbeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences
Company CEO to Co-Chair Symposium being held on April 11th in NYC NEW YORK and CLEVELAND, April 05, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening
Read more →ABEOAbeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights Management to Host Investor Conference Call on Monday, April 10 th at 10:00 am ET to Provide Progress Report on Corporate Developments NEW YOR
Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights to Host Investor Conference Call on Monday, April 10th at 10:00 am ET to Provide Progress Report on Corporate Developments NEW YORK, NY and CLEVELAND, OH - March 31, 2017 -- Abeona Therapeutics Inc
Read more →ABEOAbeona Therapeutics to Present at Multiple Upcoming Investor Conferences
NEW YORK and CLEVELAND, March 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced Chief Operating Officer, Jeffrey B. Da
Read more →ABEOAbeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
Abeona’s Fourth Gene Therapy Program to Receive EMA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in Ongoing Phase 1/2 Clinical Trial NEW YORK and CLEVELAND, March 08, 2017 (GLOBE NEWS
Read more →ABEOAbeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
NEW YORK and CLEVELAND, March 07, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced Chief Operating Officer, Jeffrey B. Dav
Read more →ABEOAbeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
NEW YORK and CLEVELAND, March 03, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced President and CEO, Timothy J. Miller,
Read more →ABEOAbeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit Securities Class Action Lawsuit lacked any valid basis and was voluntarily dismissed New York, NY, and Cleveland, OH
Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit Securities Class Action Lawsuit lacked any valid basis and was voluntarily dismissed New York, NY, and Cleveland, OH - February 23, 2017 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-s
Read more →ABEOAbeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
Company CEO and COO Presentations to be Held on Wednesday, February 22nd NEW YORK and CLEVELAND, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare
Read more →ABEONASDAQ: ABEO www.abeonatherapeutics.com Safe Harbor Statement This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, inc
NASDAQ: ABEO www.abeonatherapeutics.com Safe Harbor Statement This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating to the product portfolio and pip
Read more →ABEOAbeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
NEW YORK and CLEVELAND, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO): ABO-102 gene therapy well-tolerated in 4 subjects (N=3 low dose, N=1 high dose) through 650 days follow up with no Serious Adverse Events 63% +/- 0.5% central nervous system reduct
Read more →ABEOAbeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017
Multiple Oral Platform Presentations and Poster Sessions Highlighting Gene Therapy Programs, Tuesday, February 14th through Thursday, February 16th NEW YORK and CLEVELAND, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharm
Read more →ABEOAbeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A
ABO-102, the leading clinical gene therapy program for Sanfilippo syndrome type A patients, has demonstrated central nervous system (CNS) and peripheral organ disease biopotency First high dose cohort patient is enrolled, and all patients (n = 4) have cumulative 644 days post-in
Read more →ABEOAbeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B
NEW YORK and CLEVELAND, Jan. 19, 2017 (GLOBE NEWSWIRE) -- ABO-101, Abeona’s third AAV gene therapy program to receive EMA Orphan Designation Clinical trials anticipated to begin enrolling in second quarter 2017 Natural History Study in 25 patients has established efficacy outc
Read more →ABEOAbeona Therapeutics to Present at Phacilitate Cell & Gene Therapy World 2017
NEW YORK and CLEVELAND, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced President and CEO, Timothy J. Miller, Ph.D., wil
Read more →ABEOAbeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease
NEW YORK, NY and CLEVELAND, OH --(Marketwired - January 03, 2017) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency (
Read more →ABEOAbeona Therapeutics to Present at 2016 Genetic Rx Boston Biotech Conference at Harvard Medical School
NEW YORK, NY and CLEVELAND, OH--(Marketwired - December 06, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced President and CEO, Timothy J. Miller
Read more →ABEOAbeona Therapeutics to Present at World Orphan and Drug Congress Europe 2016
NEW YORK, NY and CLEVELAND, OH--(Marketwired - November 15, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Mill
Read more →ABEOAbeona Therapeutics Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights Investor Conference Call to be held Friday, November 18 at 10:30 am ET NEW YORK, NY and CLEVELAND, OH
Abeona Therapeutics Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights Conference Call to be held Friday, November 18 at 10:30 am ET NEW YORK, NY and CLEVELAND, OH - November 10, 2016 -- Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage bioph
Read more →ABEOAbeona Therapeutics Honored with Partner in Progress Award from DEBRA of America
NEW YORK, NY and CLEVELAND, OH--(Marketwired - November 05, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced the Company was honored with a Partn
Read more →ABEOAbeona Therapeutics to Present at Alliance of Regenerative Medicine 4th Annual Advanced Therapies Investor Day in London, UK
NEW YORK, NY and CLEVELAND, OH--(Marketwired - November 03, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Mil
Read more →ABEOAbeona Therapeutics Announces JAMA Publication of Positive Phase 1 Study Results for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
NEW YORK, NY and CLEVELAND, OH--(Marketwired - November 02, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO): EB-101 Phase 1 clinical trial therapy demonstrated clinical efficacy of 67% healed wounds at 6 month post-treatment, lasting through 12 months, including collagen biomark
Read more →ABEOAbeona Therapeutics Inc. Announces Closing of its Underwritten Offering of Common Stock New York, NY, and Cleveland, OH
Abeona Therapeutics Inc. Announces Closing of its Underwritten Offering of Common Stock New York, NY, and Cleveland, OH - November 1, 2016 - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing therapies for life-threatenin
Read more →ABEOAbeona Therapeutics Announces Pricing of Public Offering of Common Stock New York, NY, and Cleveland, OH
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock New York, NY, and Cleveland, OH - October 27, 2016 - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic
Read more →ABEOAbeona Therapeutics Announces Public Offering of Common Stock New York, NY, and Cleveland, OH
Abeona Therapeutics Announces Public Offering of Common Stock New York, NY, and Cleveland, OH - October 26, 2016 - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, t
Read more →ABEOAbeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo Syndrome Type A Fast Track Designation Added to Already Granted Orphan Drug Designation by the FDA and European Medicines Agency (EM
Abeona Therapeutics Announces Fast Track from FDA for ABO-102 in Sanfilippo Syndrome Type A Fast Track Designation Added to Already Granted Orphan Drug Designation by the FDA and European Medicines Agency (EMA), and Rare Pediatric Disease Designation for ABO-102 in Sanfilipp
Read more →ABEOTherapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at
Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK New York, NY, and Cleveland, OH - October 20, 2016 - Abeona Therapeutics Inc. (Nasdaq: ABEO): Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-
Read more →ABEOAbeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK
NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 20, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO): ABO-102 gene therapy well-tolerated at low-dose Cohort of 3 subjects Significant average GAG (heparan sulfate) reduction in urine (57.6% +/- 8.2%) and cerebral spinal flu
Read more →ABEOAbeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-102 Gene Therapy in Sanfilippo Syndrome Type A
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - October 18, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical- stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency (EM
Read more →ABEOAbeona Therapeutics to Present Top-Line Data of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients at Upcoming Orphan Drugs and Rare Disease Congress October 19-20th in London, UK
NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 14, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that top-line results of the low-dose co
Read more →ABEOAbeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of Juvenile Batten Disease Gene Therapy
NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 07, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO): Preclinical efficacy data demonstrated corrected motor deficits, attenuated neuroinflammation and reduced lysosomal throughout the central nervous system (CNS) and periphe
Read more →ABEOAbeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A
NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 05, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) ABO-102 (AAV-SGSH) delivers first-in-man AAV-based gene therapy administered by single intravenous injection to treat CNS and peripheral manifestations of Sanfilippo syndro
Read more →ABEOAbeona Therapeutics to Present at Jefferies Gene Editing & Gene Therapy Summit
NEW YORK, NY and CLEVELAND, OH --(Marketwired - October 04, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Mill
Read more →ABEOAbeona Therapeutics to Present at Cell Gene Meeting on the Mesa
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 29, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Mil
Read more →ABEOAbeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 26, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) Phase 1 clinical trial in five patients demonstrated EB-101 (gene corrected skin grafts) was well tolerated and demonstrated promising clinical efficacy in patients for t
Read more →ABEOAbeona Therapeutics to Present at Ladenburg Thalmann 2016 Healthcare Conference
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 23, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that COO Jeffrey Davis, will be pres
Read more →ABEOAbeona Therapeutics Announces Licensing of the AIM(TM) Next Generation AAV Gene Therapy Vector Platform From The University of North Carolina at Chapel Hill
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - September 21, 2016) - AIM™ vector system is a novel AAV-based vector technology platform that may target CNS and other tissues with increased efficiency and tissue specificity Exclusive worldwide license adds ABO-202, an AAV gene
Read more →ABEOAbeona Therapeutics to Present at 2016 Aegis Growth Conference
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 16, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing gene and plasma-based therapies for life- threatening rare genetic diseases, today announced that Abeona T
Read more →ABEOAbeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of MPS IIIA Gene Therapy
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - September 15, 2016) - Preclinical efficacy data demonstrated significant benefits leading to restoration of SGSH activity and reduction of glycosaminoglycans (GAG) throughout the central nervous system (CNS) and peripheral organs
Read more →ABEOAbeona Therapeutics Enrolls 5th Patient in Phase 1/2 Gene Therapy Clinical Trial for Epidermolysis Bullosa
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 08, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) EB-101 (gene-corrected skin grafts) has demonstrated promising clinical efficacy in patients for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) Phase
Read more →ABEOAbeona Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 07, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing gene and plasma-based therapies for life- threatening rare genetic diseases, today announced that COO, Jef
Read more →ABEOAbeona Therapeutics to Present at Landmark Angels 6th Annual Investing for Cures 2016 Conference
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 01, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing gene and plasma-based therapies for life-threatening rare genetic diseases, today announced that COO, Jef
Read more →ABEOAbeona Therapeutics Completes Enrollment of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 29, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO): Low-dose cohort (n=3) enrollment completed for ongoing study to evaluate ABO-102 (AAV-SGSH), first-in-man AAV gene therapy by single intravenous injection in patients with
Read more →ABEOAbeona Therapeutics Announces Second Quarter 2016 Financial Results and Recent Clinical Highlights Investor Conference Call to be held Wednesday, August 17 th at 10:00 am ET New York, NY and Cleveland, OH
Announces Second Quarter 2016 Financial Results and Recent Clinical Highlights Wednesday, August 17th at 10:00 am ET New York, NY and Cleveland, OH - August 16, 2016 - Abeona Therapeutics Inc. (Nasdaq: ABEO) a clinical-stage biopharmaceutical company focused on delivering gen
Read more →ABEOAbeona Therapeutics, EB Research Partnership and EB Medical Research Foundation to Collaborate on Epidermolysis Bullosa (EB) Treatments New York, NY and Cleveland, OH
Abeona Therapeutics, EB Research Partnership and EB Medical Research Foundation to Collaborate on Epidermolysis Bullosa (EB) Treatments New York, NY and Cleveland, OH - August 9, 2016 - Abeona Therapeutics Inc. (Nasdaq: ABEO) Abeona Therapeutics Inc. (Nasdaq: ABEO ), a clini
Read more →ABEOAbeona Therapeutics Announces European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 04, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO) Approval of clinical trial for ABO-102 (AAV-SGSH) in European Union marks 3rd regulatory approval for the company, 2nd for ABO-102 Approval following encouraging safety pr
Read more →ABEOAbeona Therapeutics Provides Update on Initial Subjects in Sanfilippo Type A Gene Therapy Trial, Demonstrating Encouraging Early Biopotency Signals
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 02, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) ABO-102 (AAV-SGSH) delivers first-in-man AAV-based gene therapy delivered by single intravenous injection to treat central nervous system and peripheral manifestations of MP
Read more →ABEOAbeona Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
NEW YORK, NY and CLEVELAND, OH--(Marketwired - June 30, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that CEO
Read more →ABEOAbeona Therapeutics to Present at Jefferies 2016 Global Healthcare Conference
NEW YORK, NY and CLEVELAND, OH--(Marketwired - June 07, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that CEO
Read more →ABEOAbeona Therapeutics to Present at 2016 BIO International Convention
NEW YORK, NY AND CLEVELAND, OH--(Marketwired - June 02, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Vice
Read more →ABEOAbeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB)
NEW YORK, NY and CLEVELAND, OH--(Marketwired - May 24, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) ABO-101 is Abeona's second AAV gene therapy to commence clinical trials in a rare CNS disease The clinical trial is a Phase 1/2 dose escalation study of ABO-101 in 6-9 patien
Read more →ABEOAbeona Therapeutics to Present at UBS 2016 Global Healthcare Conference
NEW YORK, NY and CLEVELAND, OH--(Marketwired - May 23, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today anno
Read more →ABEOAbeona Therapeutics Doses First Patient in Phase 1/2 Trial With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
NEW YORK, NY and CLEVELAND, OH--(Marketwired - May 17, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing products for severe and life-threatening rare genetic diseases, announced today that the first patient in a Pha
Read more →ABEOAbeona Therapeutics Announces First Quarter 2016 Summary Financial Results and Recent Operational Highlights
NEW YORK, NY and CLEVELAND, OH--(Marketwired - May 16, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today anno
Read more →ABEOAbeona Therapeutics Appoints Christine Silverstein as Vice President of Investor Relations
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - May 03, 2016) - Abeona Therapeutics Inc (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering products for severe and life-threatening rare diseases, announced today that it has appointed Christine Silvers
Read more →ABEOAbeona Therapeutics to Present at Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - April 15, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today
Read more →ABEOAbeona Therapeutics to Present at Alliance of Regenerative Medicine's (ARM) 4th Annual Cell & Gene Therapy Investor Day
NEW YORK, NY AND CLEVELAND, OH--(Marketwired - March 21, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that
Read more →ABEOAbeona Therapeutics to Present at the 28th Annual ROTH Conference
NEW YORK, NY and CLEVELAND, OH --(Marketwired - March 10, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that
Read more →ABEOAbeona Therapeutics Announces Fourth Quarter and Full Year 2015 Summary Financial Results and Recent Operational Highlights
NEW YORK, NY and CLEVELAND, OH--(Marketwired - March 08, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced summa
Read more →ABEOAbeona Therapeutics Highlights New Preclinical Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) Data at WORLDSymposium(TM) 2016
NEW YORK, NY and CLEVELAND, OH--(Marketwired - March 02, 2016) - AB0-201 (AAV CLN3) demonstrates promising in vivo efficacy in preclinical models IND enabling toxicology to commence in 2016 Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on develo
Read more →ABEOAbeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Systemic AAV Phase 1/2 Clinical Study With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
NEW YORK, NY and CLEVELAND, OH--(Marketwired - February 29, 2016) - Phase 1/2 dose escalation study of ABO-102 in 6-9 patients Natural history study in 25 patients establishes baseline for efficacy endpoints FDA previously granted both Orphan Drug Designation and Rare Pediatri
Read more →ABEOAbeona Therapeutics, Inc. to Present on CRISPR/CAS9 Technology Platform Progress at CRISPR Precision Gene Editing Congress
NEW YORK, NY and CLEVELAND, OH--(Marketwired - February 24, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced be
Read more →ABEOAbeona Therapeutics to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
DALLAS, TX and NEW YORK, NY--(Marketwired - February 09, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that J
Read more →ABEOAbeona Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
DALLAS, TX and NEW YORK, NY--(Marketwired - February 04, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that J
Read more →ABEOAbeona Therapeutics Announces Initial European Regulatory Approvals for Phase 1/2 Gene Therapy Clinical Studies for Patients With Sanfilippo Syndromes Type A (MPS IIIA) and Type B (MPS IIIB)
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - January 11, 2016) - Approval of Genetically Modified Organism (GMO) and Ethical Committee (CEIC) regulatory filings for both ABO-101 (AAV-NAGLU) and ABO-102 (AAV-SGSH) in Spain Phase 1/2 dose escalation studies of ABO-101 and ABO-
Read more →ABEONASDAQ: ABEO www.abeonatherapeutics.com 1 Safe Harbor Statement This presentation contains certain statements that may be forward - looking within the meaning of Section 27a of the Securities Act of 1933, as amended, inc
NASDAQ: ABEO www.abeonatherapeutics.com 1 Safe Harbor Statement This presentation contains certain statements that may be forward - looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio and pip
Read more →ABEOAbeona Therapeutics to Present at Piper Jaffray 27th Annual Healthcare Conference
NEW YORK, NY--(Marketwired - December 01, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Tim Miller, Ph.D
Read more →ABEOAbeona Therapeutics to Present at Jefferies 2015 Global Healthcare Conference
NEW YORK, NY--(Marketwired - November 18, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Tim Miller, Ph.D
Read more →ABEOAbeona Therapeutics Reports Financial Results and Highlights for Third Quarter 2015
NEW YORK, NY and CLEVELAND, OH--(Marketwired - November 17, 2015) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced its financ
Read more →ABEOAbeona Therapeutics Announces License for Next Generation AAV Delivery Vector for Fanconi Anemia and Rare Blood Disease Platform
NEW YORK, NY--(Marketwired - October 06, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO) License enables lead CRISPR/Cas9 program for ABO-301 (AAV-FANCC) for Fanconi anemia and rare blood disorder platform CRISPR/Cas9 mediated FANCC correction has demonstrated efficacy in cell
Read more →ABEOAbeona Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
NEW YORK, NY--(Marketwired - October 01, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Tim Miller, Ph.D.
Read more →ABEOAbeona Therapeutics to Present at 2015 Rodman & Renshaw Annual Global Investment Conference
NEW YORK, NY--(Marketwired - September 03, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Tim Miller, Ph.
Read more →ABEOAbeona Therapeutics to Present at the 2015 Sidoti Emerging Growth Conference
NEW YORK, NY--(Marketwired - August 24, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Tim Miller, Ph.D.,
Read more →ABEOAbeona Therapeutics Announces Recent Highlights and Second Quarter 2015 Conference Call
NEW YORK, NY--(Marketwired - August 17, 2015) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, will provide a business update for inves
Read more →ABEOAnnounces Closing of Upsized $15.5 Million Equity Financing with Institutional Investors and Management
Announces Closing of Upsized $15.5 Million Equity Financing with Institutional Investors and Management New York, NY, August 3, 2015 - Abeona Therapeutics, Inc. (Nasdaq: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based produc
Read more →ABEOAbeona Therapeutics Announces Closing of Upsized $15.5 Million Equity Financing With Institutional Investors and Management
NEW YORK, NY--(Marketwired - August 03, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced it had closed an upsize
Read more →ABEOAbeona Therapeutics Announces $8.5 Million Equity Financing With Current Institutional Investors and Directors
NEW YORK, NY--(Marketwired - July 28, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced it had entered into a def
Read more →ABEOAbeona Therapeutics Provides Update on SDF(TM) (Salt Diafiltration) Plasma Fractionation Products
NEW YORK, NY--(Marketwired - July 07, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO) Confirms SDF™ technology platform fractions provide significantly enhanced yields of PTB-101 SDF Alpha™ (alpha1-proteinase inhibitor) for inherited COPD; and PTB-201 SDF IVIG™ (intravenous imm
Read more →ABEOAbeona Therapeutics Raises Additional $4.6 Million Through Warrant Exercises in Q2 15
NEW YORK, NY--(Marketwired - July 01, 2015) - Abeona Therapeutics, Inc. (NASDAQ: ABEO) Financings of approximately $40 million completed to advance rare disease product development Abeona Therapeutics joins Russell Global, Russell 3000® and Russell MicroCap® Indexes Abeona The
Read more →ABEOPlasmaTech Biopharmaceuticals Announces Name Change to Abeona Therapeutics to Reflect Broader Rare Disease Commitment Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for
PlasmaTech Biopharmaceuticals Announces Name Change to Abeona Therapeutics to Reflect New York, NY, June 19 2015 - PlasmaTech Biopharmaceuticals, Inc. (Nasdaq: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for s
Read more →ABEOAbeona Therapeutics Set to Join Russell Global, Russell 3000(R) and Russell MicroCap(R) Indexes
NEW YORK, NY--(Marketwired - June 22, 2015) - Abeona Therapeutics begins trading today under ticker symbol ABEO Company to ring NASDAQ closing bell today at 4:00 pm ET Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering ge
Read more →ABEOAbeona Therapeutics (Nasdaq: ABEO), formerly known as PlasmaTech Biopharmaceuticals, Inc. to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, June 19, 2015 (GLOBE NEWSWIRE) -- PlasmaTech Biopharmaceuticals announces name change to Abeona Therapeutics (Nasdaq:ABEO) to Reflect Broader Rare Disease Commitment and will visit the Nasdaq MarketSite in Times Square on Monday, June 22nd. Abeona Therapeutics is a bio
Read more →ABEOPLASMATECH BIOPHARMACEUTICALS CLOSES ABEONA THERAPEUTICS ACQUISITION Two Phase 1/2 Clinical Trials for ABX-101 (MPS IIIB) and ABX-102 (MPS IIIA) For Sanfilippo Syndrome to Commence This Year New York, NY
PLASMATECH BIOPHARMACEUTICALS CLOSES ABEONA THERAPEUTICS ACQUISITION Two Phase 1/2 Clinical Trials for ABX-101 (MPS IIIB) and ABX-102 (MPS IIIA) For Sanfilippo Syndrome to Commence This Year New York, NY, May 18, 2015 - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biop
Read more →ABEOPLASMATECH BIOPHARMACEUTICALS CLOSES $10 MILLION FINANCING Proceeds To Support Clinical Development Of Gene & Cell Therapy Programs In Inherited COPD and Sanfilippo Syndromes (MPS IIIA & MPS IIIB) Dallas, TX and New York
Dallas, TX and New York, NY, May 11, 2015 -- PlasmaTech Biopharmaceuticals, Inc. ("PlasmaTech" or the "Company"), (Nasdaq: PTBI), a biopharmaceutical company focused on advancing cell therapy and gene therapy for rare diseases, announced today that it closed the previously announ
Read more →ABEONASDAQ: PTBI Investor Presentation This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating
NASDAQ: PTBI Investor Presentation This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating to the product portfolio and pipeline and clinical programs
Read more →ABEOPLASMATECH BIOPHARMACEUTICALS ANNOUNCES AGREEMENT TO ACQUIRE ABEONA THERAPEUTICS LLC Company is well positioned to execute on its strategy to become a leader in cell therapy and gene therapy for rare diseases Abeona's pr
PLASMATECH BIOPHARMACEUTICALS ANNOUNCES AGREEMENT TO ACQUIRE ABEONA THERAPEUTICS LLC Company is well positioned to execute on its strategy to become a leader in cell therapy and gene therapy for rare diseases Abeona's preclinical studies have demonstrated promising efficacy in
Read more →ABEOPlasmaTech News PLASMATECH BIOPHARMACEUTICALS ANNOUNCES CLOSING OF UPSIZED $7 MILLION PRIVATE PLACEMENT DALLAS, TX and
PLASMATECH BIOPHARMACEUTICALS ANNOUNCES CLOSING OF UPSIZED $7 MILLION PRIVATE PLACEMENT DALLAS, TX and NEW YORK, NY - April 24, 2015 - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive car
Read more →ABEOPlasmaTech Biopharmaceuticals, Inc. (logo) PlasmaTech News PLASMATECH BIOPHARMACEUTICALS' ANNOUNCES $5 MILLION PRIVATE PLACEMENT Dallas, TX and New York, NY
PlasmaTech Biopharmaceuticals, Inc. (logo) PLASMATECH BIOPHARMACEUTICALS' ANNOUNCES $5 MILLION PRIVATE PLACEMENT Dallas, TX and New York, NY, April 2, 2015 - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and
Read more →ABEOCompany Overview Q1 2015 This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating to the pro
Company Overview Q1 2015 This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating to the product portfolio and pipeline and clinical programs of the co
Read more →ABEOInvestor Presentation January 2015 This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating
Investor Presentation January 2015 This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating to the product portfolio and pipeline and clinical programs
Read more →ABEOENTITLED PLASMA TECH ANNOUNCES CLOSING OF PUBLIC OFFERING Unassociated Document PlasmaTech News Company and Media Contact: Harrison Wehner President & CFO PlasmaTech Biopharmaceuticals, Inc. (617) 981-6955
Company and Media Contact: PlasmaTech Biopharmaceuticals, Inc. PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering Dallas, TX and New York, NY, December 24, 2014 - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company adva
Read more →ABEOPlasmaTech News Company and Media Contact: Harrison Wehner President & CFO PlasmaTech Biopharmaceuticals, Inc. (617) 981-6955 PlasmaTech Biopharmaceuticals, Inc. Announces Pricing of $14,000,000 Public Offering and Listi
Company and Media Contact: PlasmaTech Biopharmaceuticals, Inc. PlasmaTech Biopharmaceuticals, Inc. Announces Pricing of $14,000,000 Public Offering and Listing on NASDAQ Dallas, TX and New York, NY, December 18, 2014 - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW),
Read more →ABEOInvestor Presentation December 2014 This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating
Investor Presentation December 2014 This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating to the product portfolio and pipeline and clinical program
Read more →ABEOPlasmaTech News Company and Media Contact: Christine Berni Vice President, Corporate Development PlasmaTech Biopharmaceuticals, Inc. (212) 786-6208 PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticke
Company and Media Contact: Vice President, Corporate Development PlasmaTech Biopharmaceuticals, Inc. PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website Company Name Officially Changes from Access Pharmaceuticals
Read more →ABEOInvestor Presentation October/November 2014 10.24.14 Final Version This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended
Investor Presentation October/November 2014 10.24.14 Final Version This presentation contains certain statements that may be forward - looking within the meaning of Section 27 a of the Securities Act of 1933 , as amended, including statements relating to the product portfolio an
Read more →ABEOAccess Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name Name Changed to PlasmaTech Biopharmaceuticals, Inc. Proprietary, Disruptive Technology for the Bioident
Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name Name Changed to PlasmaTech Biopharmaceuticals, Inc. Proprietary, Disruptive Technology for the Bioidentical Therapeutics Business DALLAS and NEW YORK, Sept. 22,
Read more →Competitive Position
How ABEO ranks across every disease it competes inCompetitive Position is a premium feature
See how ABEO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial